rs61742245

This is a missense variant in the VKORC1 gene.

Key Literature Trait Associations

Warfarin Resistance

VKORC1 Asp36Tyr is a rare missense variant that causes warfarin resistance by directly altering the drug binding site on vitamin K epoxide reductase. Carriers require dramatically higher warfarin doses, sometimes exceeding 10 mg/day, to achieve therapeutic anticoagulation. This variant should be suspected when patients show unexpectedly poor response to standard or even elevated warfarin doses.

Brown KC et al. Drug interactions with new and investigational antiretrovirals. Clinical Pharmacokinetics 48(4):211-241 (2009)
Allele T
OR
p
Candidate gene study

ClinVar annotation

Drug Response★★★★
10 submitters10 publications

Warfarin response; Vitamin K-dependent clotting factors, combined deficiency of, type 2; not provided; Thrombus; not specified; warfarin response - Dosage; VKORC1-related disorder

View on ClinVar →

Research that mentions this SNP (1)

VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China
AssociationN=260Qiang Gu et al.(2010)· European Journal of Clinical Pharmacology

Study of 127 southwest Chinese Han patients with mechanical heart valve prostheses examined genetic polymorphisms in VKORC1 -1639G>A (rs9923231), CYP2C9 (*3: rs1057910, IVS3-65G>C: rs9332127), and EPHX1 691A>G (rs4653436) as predictors of warfarin maintenance dosage. A multiple linear regression model incorporating these genetic variants plus age and body weight explained 74.3% of interindividual variability in warfarin dosing, with VKORC1 -1639G>A being the strongest predictor (r=0.769, p<0.001).

Traits studied:Anticoagulation response in mechanical heart valve prosthesis patientsWarfarin maintenance dosage

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…